Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
NCT06873789Phase 2Terminated
- Sponsor
- Incyte
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of INCB177054 in solid tumor, head and neck squamous cell carcinoma (HNSCC), anal canal squamous cell carcinoma (SCCA) and 1 more (5 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-emergent Adverse Events at 45 days and 1 more. Started Jun 2025; status: terminated.
02
Drugs
INCB177054
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)anal canal squamous cell carcinoma (SCCA)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06873789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873789.